Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

Vincenzo Russo, Andrea Stella, Antonio Barone, Ingrid Scott, Nicola Delle Noci

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalInternational Ophthalmology
Issue number1
StatePublished - Feb 1 2012

All Science Journal Classification (ASJC) codes

  • Ophthalmology


Dive into the research topics of 'Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma'. Together they form a unique fingerprint.

Cite this